Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Obesity cannabidiol:

Endocannabinoid System: A Multi-Facet Therapeutic Target. Kaur R et al. Curr Clin Pharmacol. (2016)

Experimental cannabidiol treatment reduces early pancreatic inflammation in type 1 diabetes. Lehmann C et al. Clin Hemorheol Microcirc. (2016)

Cannabidiol promotes browning in 3T3-L1 adipocytes. Parray HA et al. Mol Cell Biochem. (2016)

Search results

Items: 1 to 20 of 24

1.

Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.

Galaj E, Xi ZX.

CNS Drugs. 2019 Oct;33(10):1001-1030. doi: 10.1007/s40263-019-00664-w.

PMID:
31549358
2.

Cannabidiol inhibits sucrose self-administration by CB1 and CB2 receptor mechanisms in rodents.

Bi GH, Galaj E, He Y, Xi ZX.

Addict Biol. 2019 Jun 19:e12783. doi: 10.1111/adb.12783. [Epub ahead of print]

PMID:
31215752
3.

VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity.

Palomares B, Ruiz-Pino F, Navarrete C, Velasco I, Sánchez-Garrido MA, Jimenez-Jimenez C, Pavicic C, Vazquez MJ, Appendino G, Bellido ML, Calzado MA, Tena-Sempere M, Muñoz E.

Sci Rep. 2018 Oct 31;8(1):16092. doi: 10.1038/s41598-018-34259-0.

4.

GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol.

Laun AS, Shrader SH, Brown KJ, Song ZH.

Acta Pharmacol Sin. 2019 Mar;40(3):300-308. doi: 10.1038/s41401-018-0031-9. Epub 2018 Jun 25. Review.

PMID:
29941868
5.

Time-dependent effect of phytocannabinoid treatments in fat cells.

Ramlugon S, Levendal RA, Frost CL.

Phytother Res. 2018 Jun;32(6):1080-1089. doi: 10.1002/ptr.6047. Epub 2018 Feb 21.

PMID:
29464872
6.

Translating Endocannabinoid Biology into Clinical Practice: Cannabidiol for Stroke Prevention.

Scharf EL.

Cannabis Cannabinoid Res. 2017 Oct 1;2(1):259-264. doi: 10.1089/can.2017.0033. eCollection 2017. Review.

7.

Endocannabinoid System: A Multi-Facet Therapeutic Target.

Kaur R, Ambwani SR, Singh S.

Curr Clin Pharmacol. 2016;11(2):110-7. Review.

PMID:
27086601
8.

Cannabidiol promotes browning in 3T3-L1 adipocytes.

Parray HA, Yun JW.

Mol Cell Biochem. 2016 May;416(1-2):131-9. doi: 10.1007/s11010-016-2702-5. Epub 2016 Apr 11.

PMID:
27067870
9.

Role of the endocannabinoid system in diabetes and diabetic complications.

Gruden G, Barutta F, Kunos G, Pacher P.

Br J Pharmacol. 2016 Apr;173(7):1116-27. doi: 10.1111/bph.13226. Epub 2015 Aug 20. Review.

10.

Activation of GPR55 Receptors Exacerbates oxLDL-Induced Lipid Accumulation and Inflammatory Responses, while Reducing Cholesterol Efflux from Human Macrophages.

Lanuti M, Talamonti E, Maccarrone M, Chiurchiù V.

PLoS One. 2015 May 13;10(5):e0126839. doi: 10.1371/journal.pone.0126839. eCollection 2015. Erratum in: PLoS One. 2015;10(6):e0131850.

11.

Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis.

Silvestri C, Paris D, Martella A, Melck D, Guadagnino I, Cawthorne M, Motta A, Di Marzo V.

J Hepatol. 2015 Jun;62(6):1382-90. doi: 10.1016/j.jhep.2015.01.001. Epub 2015 Jan 13.

PMID:
25595882
12.

Cannabinoids and schizophrenia: therapeutic prospects.

Robson PJ, Guy GW, Di Marzo V.

Curr Pharm Des. 2014;20(13):2194-204. Review.

PMID:
23829368
13.

Cannabis and Δ9-tetrahydrocannabinol (THC) for weight loss?

Le Foll B, Trigo JM, Sharkey KA, Le Strat Y.

Med Hypotheses. 2013 May;80(5):564-7. doi: 10.1016/j.mehy.2013.01.019. Epub 2013 Feb 11.

PMID:
23410498
14.

Cannabinol and cannabidiol exert opposing effects on rat feeding patterns.

Farrimond JA, Whalley BJ, Williams CM.

Psychopharmacology (Berl). 2012 Sep;223(1):117-29. doi: 10.1007/s00213-012-2697-x. Epub 2012 Apr 28.

PMID:
22543671
15.

[The potential use of cannabidiol in the therapy of metabolic syndrome].

Kleiner D, Ditrói K.

Orv Hetil. 2012 Apr 1;153(13):499-504. doi: 10.1556/OH.2012.29308. Review. Hungarian.

PMID:
22430005
16.

The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications.

Horváth B, Mukhopadhyay P, Haskó G, Pacher P.

Am J Pathol. 2012 Feb;180(2):432-42. doi: 10.1016/j.ajpath.2011.11.003. Epub 2011 Dec 5. Review.

17.

Screening for Selective Ligands for GPR55 - Antagonists.

Heynen-Genel S, Dahl R, Shi S, Milan L, Hariharan S, Sergienko E, Hedrick M, Dad S, Stonich D, Su Y, Vicchiarelli M, Mangravita-Novo A, Smith LH, Chung TDY, Sharir H, Caron MG, Barak LS, Abood ME.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2010 Oct 30 [updated 2011 May 26].

18.

A role for the putative cannabinoid receptor GPR55 in the islets of Langerhans.

Romero-Zerbo SY, Rafacho A, Díaz-Arteaga A, Suárez J, Quesada I, Imbernon M, Ross RA, Dieguez C, Rodríguez de Fonseca F, Nogueiras R, Nadal A, Bermúdez-Silva FJ.

J Endocrinol. 2011 Nov;211(2):177-85. doi: 10.1530/JOE-11-0166. Epub 2011 Sep 1.

PMID:
21885477
19.

Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes.

Di Marzo V, Piscitelli F, Mechoulam R.

Handb Exp Pharmacol. 2011;(203):75-104. doi: 10.1007/978-3-642-17214-4_4. Review.

PMID:
21484568
20.

Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb.

Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R.

Trends Pharmacol Sci. 2009 Oct;30(10):515-27. doi: 10.1016/j.tips.2009.07.006. Epub 2009 Sep 2. Review. Erratum in: Trends Pharmacol Sci. 2009 Dec;30(12):609.

PMID:
19729208

Supplemental Content

Loading ...
Support Center